The Russian “Covid-globulin” enters the clinical trial stage

The drug "Covid-globulin" relieves the severity of the symptoms of the disease and helps to enhance immunity until recovery from it.

The drug cures while the vaccine protects

After the completion of the second and third phases of clinical trials, “Covid-globulin” will be used in the treatment of moderate and severe cases of Covid-19 infection. Globulin was prepared from plasma extracted from the blood of people recovering from Corona virus, and it differs from the Sputnik-V and ApiVac vaccines. Corona, because it contributes to the recovery from infection, not its prevention.

MOSCOW - The Russian Federal Biomedical Agency announced that the drug "Covid-globulin", the first registered immune drug in the world, is currently undergoing clinical trials.

“The first phase of clinical trials of a drug prepared in the laboratory of the Rostec Corporation Immuno-Natsymbio Corporation, which is a unique anti-Covid immunoglobulin, is taking place,” Olga Eichler, head of the medical support department at the Russian Federal Biomedical Agency, said in a statement on the sidelines of the East Economic Forum.

In early April, the Russian Ministry of Health recorded the world's first distinct immunoglobulin for the Corona virus, based on the blood plasma of people recovering from the disease. After the completion of the second and third phases of clinical trials, it is expected that the drug will be used in the treatment of moderate and severe cases of Covid-19 infection.

And the health authorities in Moscow announced the launch of the second phase of testing a drug “Covid-globulin” to treat the Corona virus. The press office of the Health Care Administration said that the experiments will include 6 hospitals in Moscow that treat people infected with the Corona virus, while the second phase of the experiments is scheduled to take two or three months.

The drug will be used to treat moderate and severe cases of corona infection

It is reported that “Covid-globulin” was synthesized on the basis of the blood plasma of people infected with the Corona virus, which contains antibodies to the virus. It is noteworthy that the drug relieves the severity of the symptoms of the disease and helps in enhancing immunity until recovery from it.

A group of scientists revealed, during the inauguration of the exhibition “Inboprom – 2021”, the first drug registered in Russia against the emerging corona virus, called “Covid-globulin”.

The scientists said that “Covid-globulin” was prepared from plasma extracted from the blood of people recovering from the Corona virus, stressing that it differs from the Sputnik-V and ApiVac Corona vaccines, because it contributes to the recovery from infection, not its prevention.

For his part, Andrei Lomakin, a consultant to the National Immunity Company, explained that the plasma of the recovered is subject to treatment and sterilization before being used in the manufacture of the Russian drug.

Lomakin added that he expects that the drug "Covid-globulin" will be allocated to moderate and serious cases of the Corona virus who are detained in the hospital only, noting that he obtained a temporary registration certificate, which is scheduled to be confirmed at the end of this year after the end of the clinical tests that he is now subject to.

The Ministry previously announced a new vaccine against the Corona virus, which is the “Epivac Corona-N” vaccine, produced by the Russian “Victor” Scientific Center. The Drug Registry of the Russian Ministry of Health stated that “Epivac Corona-N” is a vaccine based on peptide antigens to prevent Covid-19 infection.

Likewise, the “Victor” Center had previously announced that the “Epivac Corona-N” vaccine is almost no different from its predecessor, “Epivac Corona”, where the difference is in the technical production features.

And the Federal Agency for Medical and Biological Research in Russia announced last July that it had obtained permission to conduct clinical tests on a new vaccine against the Corona virus that it had developed.

A statement by the agency indicated that it had obtained official permission from the Russian Ministry of Health to conduct the first and second phases of clinical tests for the vaccine from anti-coronavirus subunits. The statement indicated that the tests will start on July 19, and 200 people between the ages of 19 and 60 will participate in them.

The agency indicated that the pre-clinical tests that concluded last June proved the safety of the new vaccine and its high preventive and immunological ability. The statement pointed out that the new vaccine aims primarily to develop cellular immunity in humans, and is vaccinated with it in two doses, with a time difference of three weeks.

Veronika Skvortsova, head of the Federal Agency for Medical and Biological Research, announced during a meeting with Russian President Vladimir Putin that the vaccine developed by the agency's experts is a new generation drug and is being developed on a new technological basis.

The plasma of the recovered is subject to treatment and sterilization before being used in the manufacture of the Russian drug

Russia has so far registered four domestically made anti-coronavirus vaccines, "Sputnik V" and "Sputnik Lite" (developed by the Gamalia Center); peptide-based API Fac Corona (developed by Vector Center); and a full-cell “Coffee Fac” (developed by the Chumakov Center).

Russia recently recorded the highest daily death rate due to Corona, since the epidemic appeared on its soil, with 808 deaths. A statement issued by the Russian Center for the Control and Prevention of Corona Virus stated that in the last 24 hours, 808 deaths were recorded due to the virus, bringing the total deaths to 168,000.

The total number of infections with the virus also increased to 6,534,791 cases, after recording 21,932 new cases. He has also recovered from infection so far in Russia, 5 million and 828 thousand and 972, while more than 537,000 are still undergoing treatment in hospitals.

Russia recorded the first infection with the Corona virus, on January 31, 2020, while it witnessed the first death due to the virus on March 19 of the same year.

And in a move that may help provide more vaccines against the Corona virus, Moscow announced the arrival of a single-dose vaccination version of the “Sputnik Lite” vaccine instead of two.

Russia launches the second stage of testing a drug “Covid-globulin” to treat the Corona virus

The Russian Investment Fund confirmed that the effectiveness of this vaccine is 79.4 percent, and its cost is less than ten dollars per dose. This announcement coincides with Russian President Vladimir Putin's support for the idea of ​​canceling patents for Covid-19 vaccines, as he urged his government to consider canceling them for Russian vaccines.

The US Centers for Disease Control and Prevention says that “for all currently authorized Covid-19 vaccines, antipyretic or analgesic drugs - such as acetaminophen and non-steroidal anti-inflammatory drugs - can be taken to treat local or systemic symptoms after vaccination, if medically appropriate. However, the routine prophylactic administration of these drugs is not currently recommended for the purpose of preventing post-vaccination symptoms, because information on the effect of such use on antibody responses induced by the COVID-19 vaccine is not yet available.